Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $10.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 120.75% from the company’s current price.

Several other brokerages also recently weighed in on TSHA. Raymond James Financial restated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Wells Fargo & Company boosted their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Finally, Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.91.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $4.53 on Tuesday. The firm’s fifty day simple moving average is $4.90 and its two-hundred day simple moving average is $4.41. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $6.02. The firm has a market capitalization of $1.24 billion, a P/E ratio of -13.73 and a beta of 1.02.

Insider Activity

In related news, insider Sukumar Nagendran sold 26,918 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $124,091.98. Following the completion of the transaction, the insider owned 1,317,389 shares of the company’s stock, valued at approximately $6,073,163.29. This trade represents a 2.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Kamran Alam sold 23,849 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $109,943.89. Following the completion of the transaction, the chief financial officer directly owned 1,443,786 shares in the company, valued at $6,655,853.46. This trade represents a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 598,623 shares of company stock valued at $2,822,188 in the last 90 days. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC increased its holdings in shares of Taysha Gene Therapies by 3.6% in the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock valued at $391,000 after purchasing an additional 2,443 shares during the period. Chicago Partners Investment Group LLC grew its position in Taysha Gene Therapies by 1.5% in the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after buying an additional 2,504 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock valued at $73,000 after buying an additional 2,765 shares during the period. Virtus Investment Advisers LLC raised its position in Taysha Gene Therapies by 7.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after buying an additional 3,008 shares during the last quarter. Finally, Xponance Inc. lifted its stake in shares of Taysha Gene Therapies by 29.1% in the 3rd quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after acquiring an additional 3,738 shares during the period. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.